Goldline Pharmaceutical IPO GMP Day 2 13 May 2026: Grey Market Holds at Rs 17, Subscription Picks Up as Issue Closes Tomorrow

May 13, 2026
Posted by: Neeraj Pandey
Category: IPO

The Goldline Pharmaceutical IPO is on Day 2 of its subscription window on 13 May 2026 with the grey market premium (GMP) holding firm at Rs 16 to Rs 17 per share, implying an expected listing price of approximately Rs 59 to Rs 60 against the upper issue price of Rs 43, a 37 to 40 percent listing premium. Day 1 saw early subscription build-up as retail investors began placing bids, but the bulk of institutional participation from QIBs (allocated 50 percent) is typically concentrated on Day 3. The Goldline Pharmaceutical IPO closes tomorrow, 14 May 2026.

The sustained GMP of Rs 16 to Rs 17 across multiple days (from 11 May through today 13 May) is one of the most stable and consistent grey market premiums among all currently open SME IPOs, signalling genuine grey market conviction in the Nagpur-based pharma marketing company. For context, RFBL Flexi Pack, which opened on the same day, has a GMP of Rs 0 versus Goldline Pharma’s Rs 17, making Goldline the standout grey market story in the current SME IPO cycle.

Table of Contents

Goldline Pharmaceutical IPO Key Details on Day 2

Exchange: BSE SME
Issue Opens: 12 May 2026
Issue Closes: 14 May 2026 (tomorrow, LAST CHANCE to apply)
Allotment Date: 15 May 2026
Credit of Shares: 18 May 2026
Listing Date: 19 May 2026
Price Band: Rs 41 to Rs 43 per share
Issue Size: Rs 11.61 crore (100% fresh issue, 27 lakh shares)
Lot Size: 3,000 shares
Minimum Retail Application: 2 lots (6,000 shares) at Rs 2,58,000
Category Split: QIB 50%, Retail 35%, NII 15%
GMP on Day 2 (13 May 2026): Rs 16 to Rs 17 (37 to 40% implied listing premium)
Implied Listing Price (GMP basis): Approximately Rs 59 to Rs 60
PE at Issue Price: 10.48 times at Rs 43 upper band
Lead Manager: Cumulative Capital Pvt Ltd
Registrar: Bigshare Services Pvt Ltd
Market Maker: Nirman Share Brokers

Track live Goldline Pharmaceutical IPO subscription on the Check the Univest Screener for live data.

Why Goldline Pharmaceutical IPO GMP Has Stayed at Rs 16-17

Highest GMP Among All Currently Open SME IPOs

The Goldline Pharmaceutical IPO GMP of Rs 16 to Rs 17 has been one of the most consistently elevated grey market premiums of the current SME IPO cycle. Sources including Investorgain and IPO Guru tracked GMP at Rs 16 to Rs 17 from 11 May through 13 May, a level of stability that is unusual and constructive. Most SME IPO GMPs fluctuate sharply with broader market sentiment. Goldline’s GMP holding despite Sensex falling 1,312 points on 11 May is a noteworthy sign of underlying grey market conviction.

Fair Valuation at 10.48x PE Supports the Premium

The Goldline Pharmaceutical IPO is priced at 10.48 times FY25 earnings at the Rs 43 upper band. Industry P/E for comparable pharmaceutical marketing companies ranges from 13 to 15 times. This discount to industry valuation means that investors are getting a pharma marketing business at a meaningful PE discount, which underpins the GMP premium. The company’s FY25 revenue of Rs 28.06 crore grew 19 percent year-on-year and PAT grew 56 percent to Rs 2.83 crore with ROE at 27.34 percent.

Tap to Access Best Research Pieces on Univest

What Day 2 Subscription Looks Like for Goldline Pharmaceutical IPO

Day 2 for SME IPOs like Goldline Pharmaceutical typically sees the NII (HNI) category begin to fill up as high-net-worth individuals assess Day 1 data. The QIB category, allocated 50 percent of the Goldline Pharmaceutical IPO (an unusually large QIB allocation for an SME), typically moves on Day 3. If QIBs show meaningful subscription by closing on 14 May, the overall book could be oversubscribed meaningfully, which would validate the Rs 17 GMP.

One independent analyst on IPO Watch flagged the large 50 percent QIB allocation as unusual for an SME IPO, noting it could affect retail allotment dynamics. Retail applicants get 35 percent of the issue. When retail subscription is below 1x, every applicant gets full allotment without a lottery. If it crosses 1x, a computerised lottery applies.

Should You Apply for Goldline Pharmaceutical IPO on Day 2

The Goldline Pharmaceutical IPO offers the highest GMP among all currently open SME IPOs at Rs 16 to Rs 17, fair PE valuation at 10.48 times and a 19 percent revenue CAGR over the past two years. For short-term investors, the GMP-implied 37 to 40 percent listing gain is attractive if it holds through the listing on 19 May.

Key risks to weigh: 22 percent of company revenue comes from promoter-related entities (related-party dependency), geographic concentration in Maharashtra (44 percent of revenue), no owned manufacturing facility and small revenue scale at Rs 28 crore. Tomorrow is the last day to apply. Consult a SEBI-registered advisor before acting on the Goldline Pharmaceutical IPO.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Goldline Pharmaceutical IPO live updates, GMP and BSE SME IPO calendar!

Conclusion

The Goldline Pharmaceutical IPO on Day 2 (13 May 2026) holds the strongest GMP among all open SME IPOs at Rs 16 to Rs 17, implying a 37 to 40 percent listing premium over the Rs 43 issue price. The nil GMP on RFBL Flexi Pack versus Rs 17 GMP on Goldline Pharma highlights the stark grey market divergence between the two co-opening SME IPOs. The issue closes tomorrow 14 May 2026. Track live subscription data and the final Day 3 QIB numbers on Univest before making your application decision.

FAQs on Goldline Pharmaceutical IPO Day 2

What is the Goldline Pharmaceutical IPO GMP on Day 2, 13 May 2026?

Ans. The Goldline Pharmaceutical IPO GMP on Day 2 stands at Rs 16 to Rs 17 per share, implying an expected listing price of Rs 59 to Rs 60 against the upper band of Rs 43. This represents a 37 to 40 percent potential listing premium, the highest GMP among all currently open SME IPOs. GMP is unofficial and can change before the 19 May listing.

When does the Goldline Pharmaceutical IPO close?

Ans. The Goldline Pharmaceutical IPO closes tomorrow, 14 May 2026, at 5 PM. Allotment is on 15 May, shares are credited on 18 May and listing on BSE SME is expected on 19 May 2026. This is the last day to apply for retail and HNI investors.

Why is Goldline Pharma GMP higher than RFBL Flexi Pack?

Ans. The Goldline Pharmaceutical IPO GMP is Rs 17 versus Rs 0 for RFBL Flexi Pack because of different grey market assessments of the two companies. Goldline’s 10.48x PE is at a steeper discount to industry versus RFBL’s 9.74x, its ROE of 27.34 percent is stronger and the pharma marketing sector has consistently attracted higher grey market interest than flexible packaging. Both issues close on 14 May.

How can I check Goldline Pharmaceutical IPO allotment status?

Ans. Goldline Pharmaceutical IPO allotment status will be available on the Bigshare Services Pvt Ltd registrar website from 15 May 2026. Check using your PAN number, application number or DP ID on the registrar portal or directly on the BSE website.

IPO GMP

Author: Neeraj Pandey

Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.